Last updated: April 23, 2026
Who supplies esketamine hydrochloride (drug substance or finished product)?
Which companies supply esketamine hydrochloride drug substance?
Commercial supply for esketamine hydrochloride is concentrated in a small set of global APIs and sterile-injectable manufacturers. In practice, procurement typically comes through two channels: (1) API/drug-substance sourcing and (2) finished-dose supply through the branded or authorized generic product supply chain.
The most commercially relevant supply entities for esketamine hydrochloride are those tied to the marketed products and their manufacturing networks:
| Supply chain role |
Representative company set |
Notes |
| Finished-dose supply (U.S. market) |
Janssen (brand) and licensed manufacturing partners |
Es ketamine hydrochloride is marketed in the U.S. as SPRAVATO (intranasal) under Janssen’s commercialization. Supplier identification for drug-substance vs finished product depends on distributor and label. |
| Drug-substance supply (API) |
Large-scale API and sterile injectables networks (global) |
API supply is handled via long-term qualification and DMF/CEP systems; visible public naming is limited to filings and regulatory documents. |
Bottom line: Public, non-submission-level supplier lists are not available in a single authoritative public dataset that cleanly enumerates “all suppliers” of the esketamine hydrochloride API worldwide. Procurement lists used by pharma are typically built from regulatory submissions, RFP responses, and qualification records tied to the specific dosage form and contract manufacturers.
Who supplies finished-dose esketamine hydrochloride?
For decision-making tied to pricing, availability, and supply risk, the finished-dose supply chain is the actionable layer:
| Product |
Typical market |
Supplier/distributor anchor |
Route |
| SPRAVATO (esketamine hydrochloride) nasal spray |
U.S. and other jurisdictions |
Janssen commercialization and its contracted manufacturing network |
Intranasal |
In the U.S., the “supplier” for operational planning is effectively the market authorization holder and its manufacturing/packaging network, because wholesalers distribute the labeled finished product under that supply chain.
What evidence-based sources confirm esketamine hydrochloride supplier anchors?
The most direct public evidence for supplier anchoring is embedded in:
1) Regulatory labels and prescribing information for the marketed product (finished-dose supply chain anchor).
2) FDA submissions and approval packages (when accessible) that list manufacturing sites for drug product and sometimes related substance manufacture.
3) European/ICH-style regulatory dossiers (DMF/CEP holders), which are not published as a universal supplier registry.
For SPRAVATO, the product is FDA-regulated as an esketamine hydrochloride-based intranasal therapy under Janssen commercialization, and the prescribing information identifies the authorized product structure and regulatory context. Source: FDA product labeling. [1]
Supplier mapping framework (what to use for sourcing decisions)
Because “supplier” can mean either API or finished product, procurement and investment diligence should map suppliers by the commercial bottleneck relevant to your use case:
| Use case |
Supplier layer to validate |
What to verify |
| Formulation development and CMC |
API/drug substance manufacturer |
DMF holder(s), impurity profile controls, crystalline form specification, particle size and polymorph control, and stability under your formulation conditions |
| Scale-up of finished dosage |
Contract manufacturer of drug product |
Sterile/non-sterile handling steps, container closure compatibility, fill-finish capability, and batch release testing scope |
| Inventory and distribution planning |
Finished-dose supply chain anchor |
Labeled product availability, wholesaler distribution reliability, and manufacturing site capacity |
What this means for “suppliers for esketamine hydrochloride”
- If you need finished-dose product for distribution or clinical use in the U.S., the supplier anchor is the SPRAVATO supply chain controlled under Janssen’s product commercialization. [1]
- If you need API, supplier identification requires dossier-level or qualification-level sourcing, because publicly searchable registers do not provide a complete global list of API holders and site-specific manufacturers for esketamine hydrochloride.
Key Takeaways
- Finished-dose supply for esketamine hydrochloride in the U.S. is anchored to SPRAVATO’s commercialization under Janssen, with contracted manufacturing and packaging sites embedded in regulatory product documentation. [1]
- API supplier lists are not available as a complete public registry; practical supplier identification relies on regulatory dossiers (DMF/CEP), qualification records, and site-specific manufacturing documents tied to the specific dosage form and market authorization.
- For supply risk and cost, prioritize validation of the finished-dose manufacturing network if your program consumes product, and validate API DMF/qualification suppliers if your program consumes drug substance.
FAQs
1) What is esketamine hydrochloride supplied as in the main commercial market?
It is supplied as SPRAVATO (esketamine hydrochloride) nasal spray in the U.S., distributed through the authorized product supply chain. [1]
2) Who controls the U.S. esketamine hydrochloride finished-dose product supply anchor?
The product is commercialized under Janssen as the labeled SPRAVATO authorization holder. [1]
3) Are there publicly available complete lists of esketamine hydrochloride API suppliers?
No single public source provides a complete global supplier registry for the API; supplier identification typically comes from dossier-level and qualification documentation rather than a universal public index.
4) What is the most relevant supplier layer for CMC development?
The esketamine hydrochloride API/drug-substance manufacturer(s) and their site-specific controls (DMF/CEP and release specs), not the finished-dose brand anchor.
5) What is the most relevant supplier layer for clinical or distribution planning?
The finished-dose manufacturing and release network for SPRAVATO or authorized generics, since supply availability in practice tracks labeled product manufacturing capacity. [1]
References
[1] U.S. Food and Drug Administration. (n.d.). SPRAVATO (esketamine hydrochloride) nasal spray prescribing information / FDA labeling. FDA. https://www.accessdata.fda.gov/
